Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer
Cancer Chemotherapy and Pharmacology, 10/21/09

Bae WK et al. – Although most patients had stage IV NPC, the TPF induction chemotherapy followed by CCRT showed promising activity with manageable toxicity. These results demonstrated the possibility of effective treatment with the aim of not only a palliative, but also a curative, approach to the treatment of advanced NPC.

Methods

Patients with advanced NPC treated with 3 cycles of induction chemotherapy
Docetaxel (70 mg/m2) and cisplatin (75 mg/m2) given on day 1, followed by 5-FU (1,000 mg/m2) as continuous infusion for 4 days
After induction chemotherapy, cisplatin given at a dose of 100 mg/m2 every 3 weeks with radiotherapy

Results

33 patients enrolled
Among the patients, 32 patients completed both induction TPF therapy and CCRT, with responses as follows: five patients (15.2%) achieved a complete response (CR), and 27 patients (81.8%) partial response (PR)
6 weeks after CCRT, 23 patients (69.7%) had a CR and 9 patients (27.3%) a PR
3-year progression-free survival 75.6% and 3-year overall survival 86.1%
Neutropenia (72.7%), febrile neutropenia (9.1%), and nausea (9.1%) were the most severe toxicities (grade 3–4) during induction chemotherapy, and mucositis (39.4%), fatigue (15.2%), and nausea (9.1%) were most common toxicities (grade 3–4) during CCRT

<< Previous
Potential predictive markers of chemotherapy resistance in stage...

Next >>
Atrophic gastritis and the risk of incident colorectal cancer